capecitabine ≠ NTID; reference-scaling [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2015-07-08 16:59 (3545 d 23:08 ago) – Posting: # 15052
Views: 15,919

Hi Mittyri,

❝ Old guidance:

Widening of the usual acceptance criteria for Cmax is not accepted because capecitabine is considered a “critical dose” drug.


and
As drug variability has not been reviewed, this guidance is not applicable to highly variables drugs.

❝ Is something changed in the minds of PKWP members? :-D


Maybe in the meantime they reviewed some data? On the other hand, a CVwR >30% is not enough to allow reference-scaling for the EMA (“sound clinical justification that a wider difference in Cmax is clinically irre­le­vant”). Given what’s stated in the guidance the EMA does not consider capecitabine a “critical dose” drug any more.
BTW, this is a Canadian term. Generally the EMA uses NTID (narrow therapeutic index drug) instead. ;-)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
20 visitors (0 registered, 20 guests [including 7 identified bots]).
Forum time: 15:08 CET (Europe/Vienna)

An expert is one who knows more and more
about less and less.    Nicholas Murray Butler

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5